TWA
VYNE icon

TCI Wealth Advisors’s VYNE Therapeutics VYNE Stock Holding History

TCI Wealth Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-153
Closed -$4K – 2543
2021
Q3 		$4K Hold
153
– – ﹤0.01% 1835
2021
Q2 		$10K Sell
153
-5
-3% -$396 ﹤0.01% 987
2021
Q1 		$20K Sell
158
-2
-1% -$290 0.01% 580
2020
Q4 		$18K Hold
160
– – 0.01% 522
2020
Q3 		$19K Buy
160
+4
+3% +$467 0.01% 461
2020
Q2 		$19K Buy
156
+148
+1,850% +$20K 0.01% 457
2020
Q1 		$2K Buy
+8
New +$2.51K ﹤0.01% 1119

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TCI Wealth Advisors's VYNE Position: Q4 2021 in Review

TCI Wealth Advisors sold out of VYNE Therapeutics (VYNE) in Q4 2021, closing a stake of 153 shares — an estimated $4K sold.

TCI Wealth Advisors first reported a position in VYNE in Q1 2020 and held it in 7 quarters. The position peaked at $20K in Q1 2021. 54 funds tracked by Wall St. Rank hold VYNE as of Q4 2021.

  • TCI Wealth Advisors reported no remaining VYNE Therapeutics position as of Q4 2021 after selling out during the quarter.
  • TCI Wealth Advisors sold 153 VYNE Therapeutics shares in Q4 2021, an estimated $4K.
  • TCI Wealth Advisors first reported a position in VYNE Therapeutics in Q1 2020 and held it in 7 quarters.
  • TCI Wealth Advisors's VYNE Therapeutics position peaked at $20K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2021.

Based on TCI Wealth Advisors's 13F filing for Q4 2021, filed 24 Jan 2022.